Cadrenal Therapeutics (CVKD) Competitors $17.60 +0.64 (+3.77%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CVKD vs. PAHC, PRTA, CGEM, RAPP, ZYME, PLRX, SANA, CRON, ANAB, and DNTHShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Phibro Animal Health (PAHC), Prothena (PRTA), Cullinan Therapeutics (CGEM), Rapport Therapeutics (RAPP), Zymeworks (ZYME), Pliant Therapeutics (PLRX), Sana Biotechnology (SANA), Cronos Group (CRON), AnaptysBio (ANAB), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Phibro Animal Health Prothena Cullinan Therapeutics Rapport Therapeutics Zymeworks Pliant Therapeutics Sana Biotechnology Cronos Group AnaptysBio Dianthus Therapeutics Phibro Animal Health (NASDAQ:PAHC) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability. Do analysts rate PAHC or CVKD? Phibro Animal Health presently has a consensus target price of $15.00, indicating a potential downside of 35.29%. Cadrenal Therapeutics has a consensus target price of $3.50, indicating a potential downside of 80.11%. Given Phibro Animal Health's higher probable upside, equities research analysts clearly believe Phibro Animal Health is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 3 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.40Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PAHC or CVKD more profitable? Phibro Animal Health has a net margin of 0.24% compared to Cadrenal Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 18.08% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health0.24% 18.08% 4.97% Cadrenal Therapeutics N/A -93.70%-82.23% Does the media favor PAHC or CVKD? In the previous week, Phibro Animal Health had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Cadrenal Therapeutics. Phibro Animal Health's average media sentiment score of 0.56 beat Cadrenal Therapeutics' score of -0.50 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadrenal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has higher valuation and earnings, PAHC or CVKD? Phibro Animal Health has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.02B0.92$2.42M$0.06386.40Cadrenal TherapeuticsN/AN/A-$8.36M-$5.55-3.17 Do insiders & institutionals believe in PAHC or CVKD? 99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, PAHC or CVKD? Phibro Animal Health has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Does the MarketBeat Community prefer PAHC or CVKD? Phibro Animal Health received 300 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 59.69% of users gave Phibro Animal Health an outperform vote. CompanyUnderperformOutperformPhibro Animal HealthOutperform Votes30559.69% Underperform Votes20640.31% Cadrenal TherapeuticsOutperform Votes5100.00% Underperform VotesNo Votes SummaryPhibro Animal Health beats Cadrenal Therapeutics on 13 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.83M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-3.179.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book1.995.324.665.02Net Income-$8.36M$153.56M$119.06M$225.46M7 Day Performance11.46%0.11%0.80%0.37%1 Month Performance47.28%15.22%5.65%3.57%1 Year PerformanceN/A41.14%36.76%29.44% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics0.8364 of 5 stars$17.60+3.8%$3.50-80.1%N/A$18.83MN/A-3.174Gap DownHigh Trading VolumePAHCPhibro Animal Health4.214 of 5 stars$23.60+0.7%$15.00-36.4%+107.1%$955.80M$1.02B393.401,940Upcoming EarningsPRTAProthena3.2104 of 5 stars$17.59+15.0%$61.86+251.7%-54.6%$945.99M$91.37M-17.59173Upcoming EarningsCGEMCullinan Therapeutics2.1469 of 5 stars$16.15+1.2%$31.67+96.1%+70.0%$930.79M$18.94M-5.2830Analyst RevisionNews CoverageRAPPRapport Therapeutics1.7493 of 5 stars$25.23+4.2%$35.00+38.7%N/A$922.91MN/A0.00N/AGap UpZYMEZymeworks1.9399 of 5 stars$13.24+2.4%$15.25+15.2%+89.2%$914.22M$62.71M-8.71290Earnings ReportAnalyst DowngradeNews CoverageGap DownPLRXPliant Therapeutics3.8911 of 5 stars$14.86+5.0%$40.57+173.0%-2.2%$903.49M$1.58M-4.8190Gap UpSANASana Biotechnology2.6444 of 5 stars$3.92+4.3%$14.25+263.5%+18.4%$872.08MN/A-3.41328Gap UpCRONCronos Group1.3282 of 5 stars$2.23+0.5%$3.00+34.5%+24.1%$852.53M$87.24M-14.87356ANABAnaptysBio3.0621 of 5 stars$30.49-4.8%$54.64+79.2%+31.1%$832.96M$30.47M-4.80100Upcoming EarningsAnalyst ForecastNews CoverageDNTHDianthus Therapeutics1.4407 of 5 stars$28.12+1.5%$45.13+60.5%+133.4%$813.26M$4.12M-5.0880Positive News Related Companies and Tools Related Companies PAHC Competitors PRTA Competitors CGEM Competitors RAPP Competitors ZYME Competitors PLRX Competitors SANA Competitors CRON Competitors ANAB Competitors DNTH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CVKD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
